Negative expression of N-acetylglucosaminyltransferase V in oral squamous cell carcinoma correlates with poor prognosis

Kahori Seto¹,²*, Fumihiko Uchida¹,²†, Osamu Baba¹,², Masanobu Yamatoji², Rei Karube¹, Eiji Warabi³, Satoshi Sakai⁵, Shogo Hasegawa², Kenji Yamagata², Toru Yanagawa², Kojiro Onizawa⁴, Eiji Miyoshi⁶, Junichi Shoda⁷, and Hiroki Bukawa²

Abstract

N-acetylglucosaminyltransferase V (GnT-V), an enzyme with a key role in the branching of asparagine-linked oligosaccharides, is strongly linked to tumor invasion and metastasis of many solid tumors. Here we searched for correlations between the clinical features of patients with oral squamous cell carcinoma (OSCC) and GnT-V expression in the tumor, and we studied the feasibility of using GnT-V as a marker for oral cancer prognosis. Samples from 68 patients with OSCC were examined by immunohistochemistry using antibodies against GnT-V. Correlations between the expression level of GnT-V in the tumor and patient clinical features were statistically analyzed. Positive GnT-V expression was found in 48 cases (70.6%), and negative GnT-V expression was found in 20 cases (29.4%). Negative GnT-V expression was associated with mode of invasion by multiple logistic regression analysis (OR: 3.605; P = 0.048). Biological characteristics of tumors and the Ki-67 labeling index were higher in tumors with negative GnT-V expression than in those with positive GnT-V expression, although the difference was not significant (P = 0.176). Patients with negative GnT-V expression had significantly shorter survival than those with tumors having positive GnT-V expression (5-year survival rate, 58.2% and 86.5%, respectively; P = 0.025). Negative GnT-V expression was a significant unfavorable prognostic factor for OSCC (hazard ratio, 4.246; P = 0.045). The loss of GnT-V expression is a likely indicator of tumors with high potential of tumor invasion and poor prognosis in OSCC patients.

Keywords: N-acetylglucosaminyltransferase V; GnT-V; Oral squamous cell carcinoma; OSCC; Biomarker

Introduction

Head and neck carcinoma, which includes cancers of the oral cavity, oropharynx, larynx, and hypopharynx, is the sixth most common cancer worldwide and has an incidence of around 600,000 cases per year (Kamangar et al. 2006). Oral cancer, the largest subset of head and neck cancer, has become one of the most lethal malignancies (Chen et al. 2013), of which oral squamous cell carcinoma (OSCC) is the most frequent histological type (Parkin et al. 2005). The current management and treatment of OSCC involves multimodal approaches comprising surgery, chemotherapy, and radiotherapy (Seiwert and Cohen 2005). Despite recent advances in early detection, diagnosis, and treatment, the 5-year survival for patients with OSCC has remained at 50% for the past 30 years (Forastiere et al. 2003). Because of the high prevalence and mortality rate of oral cancers, prevention and early intervention are important strategies for managing the disease.

Glycosylation of cell-surface glycoproteins is widely accepted to play a key role in various specific biological interactions. The glycosyltransferase plays a crucial role on the protein glycosylation. Glycosyltransferase, located in the Golgi apparatus, includes at least six N-acetylglucosaminyltransferase (GnT) defined as GnT-I-VI (Taniguchi et al. 1999). GnT-V, a glycosyltransferase encoded by the Mbat5 gene that catalyzes the formation
of β1,6GlcNAc (N-acetylglucosamine) branches on N-glycans, is believed to be associated with cancer growth and metastasis (Taniguchi et al. 1999; Lau and Dennis 2008). Moreover GnT-V protein could results in tumor angiogenesis, and its mechanism as an inducer of angiogenesis was different from original function as a glycosyltransferase (Saito et al. 2002).

Numerous studies have shown that GnT-V is positively correlated with malignancy in many types of tumor, including breast, colon, endometrial, and ovarian mucinous tumors (Fernandes et al. 1991; Murata et al. 2000; Yamamoto et al. 2007; Takahashi et al. 2009). In contrast, the opposite results have been found for lung, thyroid, and liver tumors. As such, GnT-V expression and its functional and prognostic significance in human cancer remain controversial. The relationship between GnT-V expression and malignancy has been studied in many types of tumor, but not in human oral SCC. In vitro analysis, it was reported that the decrease in β1,6GlcNAc branching on cisplatin-resistant human SCC cell line, so the GnT-V expression in SCC may be inversely correlated with prognosis (Nakahara et al. 2003).

In this study, we examined GnT-V expression by immunohistochemistry for surgically resected OSCC and analyzed the correlation with clinical features of OSCC.

**Materials and methods**

**Patients and tissue specimens**

Tumor specimens were obtained from 68 patients with OSCC seen at the Department of Oral and Maxillofacial Surgery, University of Tsukuba Hospital, Ibaraki, Japan during the period 1994–2004. Patients were followed for more than 60 months. Tumors were staged according to the International Union Against Cancer scheme (Sobin and Wittekind 1997), and clinical data were obtained from patient medical records. Specimens were obtained after patients gave informed consent, and the study protocol was reviewed and approved by the Research Ethics Committee of the University of Tsukuba (H25-43).

**Immunohistochemistry**

For immunostaining of GnT-V, 2-μm thick sections from patient samples were stained using the Vecta staining kit according to the manufacturer’s instructions with anti-GnT-V antibody obtained from Dr. Eiji Miyoshi (Osaka University, Osaka, Japan). GnT-V expression levels were classified into two groups according to the percentage of positively stained cells in the cancerous area: ≥ 30% (positive) and < 30% (negative) (Takahashi et al. 2009).
et al. 2009) (Figure 1). The scoring procedure was carried out twice by two independent observers who were blinded to the clinical data.

**Table 1 Relationship between GnT-V expression and clinical and clinicopathological characteristics in all 68 patients**

|                      | GnT-V positive | GnT-V negative | P    |
|----------------------|----------------|----------------|------|
| **Age**              |                |                |      |
| Average              | 68.88          | 59.15          | 0.006|
| **Gender**           |                |                |      |
| Male                 | 22             | 15             |      |
| Female               | 26             | 5              | 0.028|
| **Alcohol**          |                |                |      |
| no                   | 33             | 8              |      |
| yes                  | 15             | 12             | 0.027|
| **Smoking**          |                |                |      |
| no                   | 32             | 9              |      |
| yes                  | 16             | 11             | 0.096|
| **T-Category**       |                |                |      |
| 1, 2                 | 30             | 13             | 0.845|
| 3, 4                 | 18             | 7              |      |
| **Clinical Stage**   |                |                |      |
| I, II                | 27             | 9              |      |
| III, IV              | 21             | 11             | 0.397|
| **Differentiation**  |                |                |      |
| Well                 | 33             | 9              |      |
| Moderate, poor       | 15             | 11             | 0.066|
| **Mode of invasion** |                |                |      |
| 1 to 3               | 32             | 7              |      |
| 4                    | 16             | 13             | 0.016|
| **pN**               |                |                |      |
| Negative             | 42             | 15             |      |
| Positive             | 6              | 5              | 0.202|
| **Recurrence**       |                |                |      |
| Negative             | 38             | 15             |      |
| Positive             | 10             | 5              | 0.178|
| **Metastasis**       |                |                |      |
| Negative             | 38             | 14             |      |
| Positive             | 10             | 6              | 0.416|
| **Survival**         |                |                |      |
| Alive                | 43             | 13             |      |
| Dead                 | 5              | 7              | 0.015|
| **Theraphy**         |                |                |      |
| Operation            | 34             | 11             |      |
| Chemoradiotherapy    | 14             | 9              | 0.208|

**Statistical analysis**

To simplify the correlation analysis of GnT-V expression with clinical features, tumors were divided into the T-category groups T1 + T2 or T3 + T4. Clinical stage was classified as I + II or III + IV, and differentiation as well- / moderately or poorly differentiated. Anneroth grade to denote tumor invasion was assigned as 1 – 3 or 4. For univariate analysis, we used the Chi-squared test, Student’s t-test, or Welch’s t-test. For multivariate analysis, we used multiple logistic regression analysis. All analysis was performed using the statistical software package SPSS.

**Results**

**Univariate analysis of GnT-V expression**

Positive GnT-V expression was observed in 48 specimens (70.6%) and negative GnT-V expression in 20 specimens (29.4%). Table 1 shows the correlation between GnT-V expression and clinicopathological features. The GnT-V-negative group included significantly more young patients (P = 0.006), more males than females (P = 0.028), alcohol consumption (P = 0.027), more invasive tumors (P = 0.016), and a higher 5-year survival rate (P = 0.015). No significant difference in GnT-V expression was observed with respect to other factors, including, smoking, T-category, clinical stage, cellular differentiation, pN positive or negative, local recurrence, lymph node metastasis, and treatment type. No difference was observed between GnT-V expression and p53 expression. Ki-67 labeling index values were higher in tumors with negative GnT-V expression than in those with positive GnT-V expression, but not significantly (P = 0.176) (Table 2).

**Table 2 The relationship between GnT-V expression and p53, ki 67 expression**

|                      | GnT-V positive | GnT-V negative | P    |
|----------------------|----------------|----------------|------|
| p53                  |                |                |      |
| Negative             | 33             | 16             |      |
| Positive             | 15             | 4              | 0.346|
| Ki67 mib index (Mean ± SD) | 140 ± 1.9 | 19.8 ± 4.6 | 0.176|

**Multivariate analysis of GnT-V expression**

The predictor variables in the 68 patients were used in a logistic regression model with GnT-V expression as the dependent variable. The logistic model was constructed using clinical variables, including age, gender, alcohol consumption, smoking, stage, differentiation, and Mode of invasion. Adjusted odds ratios (OR) and P values are shown in Table 3. Negative staining for GnT-V (OR = 3.605 and P = 0.048) was significantly associated with invasion but not with the other variables.
Table 3 Multiple logistic regression analysis for the correlation between GnT-V expression and clinical characteristics

| Characteristics                  | Odds ratio | P   |
|----------------------------------|------------|-----|
| Age                              | 1.048      | 0.052 |
| Gender (male/female)             | 0.502      | 0.415 |
| Alcohol (no alcohol/alcohol drinker) | 1.750      | 0.464 |
| Smoking (non smoker/smoker)      | 1.378      | 0.639 |
| Stage (I + II/III + IV)          | 1.135      | 0.866 |
| Differentiation (well/moderate + poor) | 1.391      | 0.597 |
| Mode of invasion (1-3/4)         | 3.605      | 0.048 |

GnT-V expression and prognosis of OSCC
We next analyzed the relationship between GnT-V expression and patient survival and the importance of GnT-V as a prognostic factor. Kaplan-Meier survival curves clearly demonstrated that patients with negative GnT-V expression had significantly shorter survival than patients with positive GnT-V expression (5-year survival rate, 58.2% and 86.5%, respectively; P = 0.025; Figure 2). Cox proportional-hazard analysis was performed to compare the impact of GnT-V expression on survival with currently used clinicopathological prognostic factors such as age, gender, alcohol consumption, smoking consumption, stage, differentiation, and GnT-V expression. Negative GnT-V expression was the only significant unfavorable prognostic factor in our analysis (hazard ratio, 4.246; P = 0.045) (Table 4).

Discussion
Glycosylation is one of the most common posttranslational protein modifications, and nearly half of all known proteins in eukaryotes are glycosylated (Saxon and Bertozzi 2001). Cell surface glycosylation not only regulates the stability and activity of structural proteins and receptors on the cell membrane, but also participates in the maintenance of cell morphology and cell-cell interactions (Hirai-Fujita et al. 2008; Krishnan et al. 2005; Rak et al. 1991). Changes in glycans are associated with many physiological and pathological events, including cell adhesion, migration, and invasion (Dennis et al. 1987).

The present report shows that GnT-V expression in OSCC is associated with age (P = 0.006), gender (P = 0.028), alcohol consumption (P = 0.027), mode of invasion (P = 0.016), and 5-year survival (P = 0.015). Although our results revealed that there were no significant differences between GnT-V expression and T or Clinical stages, it was reported that GnT-V expression is upregulated in the early stages of almost all cancers (Miyoshi et al. 2012). However, multiple logistic regression analysis to determine the correlation between GnT-V expression and clinical and clinicopathological characteristics showed that the cases of negative GnT-V expression tended to be more invasive as determined by Anneroth grade.

Kaplan-Meier survival curves clearly demonstrated that patients with negative GnT-V expression had significantly shorter survival than patients with positive GnT-V expression (5-year survival rate, 58.2% and 86.5%, respectively; P = 0.025; Figure 2). Histology was significantly correlated with GnT-V expression and low GnT-V expression was more frequently found in squamous cell carcinomas than non-squamous cell carcinomas (Akita 2004). Our data strongly suggested that the relationship between GnT-V expression and the prognosis depends on the histological type, as well as the original organ of the cancer. When considering survival rate, the type of treatment (surgery or chemoradiotherapy) was taken into account, but we found no significant correlation between GnT-V expression and treatment type. Moreover, in patients with negative GnT-V expression that correlated with survival rate, we found no significant relationship between GnT-V expression and the prognosis depends on the histological type, as well as the original organ of the cancer.

Figure 2 Kaplan Meier disease-free survival of GnT-V expression in all patients. The 5-year disease-free survival (DFS) rates of positive GnT-V expression and negative GnT-V expression were 86.5 % and 58.2%, respectively (P = 0.025).
correlation between GnT-V expression and local recurrence or node metastasis. This suggests that negative GnT-V expression reduces the efficacy of chemoradiotherapy as a second treatment. This implies that OSCC patients with negative GnT-V expression are more likely to have poor prognosis.

The relationship between cisplatin-resistance and α5β1 integrin with β1-6GlcNAc branching has been reported in an established cisplatin-resistant head and neck carcinoma cell line, but reasons for the relationship are unclear (Nakahara et al. 2003). Down-regulation of GnT-V enhances nasopharyngeal carcinoma cell radiosensitivity both in vitro and in vivo, and is linked to the G2-M cell cycle arrest and the reduction of the Bcl-2/Bax ratio (Zhuo et al. 2012). Conversely, a correlation was found between the high expression levels of GnT-V in neuroblastoma patients with a favorable prognosis, suggesting that GnT-V can cause neuroblastomas to regress by increasing their susceptibility to apoptosis (Inamori et al. 2006).

Low expression of GnT-V may contribute to altered biological properties of bladder cancer as well as non-small cell lung cancer and hepatocellular carcinoma by decreasing the synthesis of β1-6 branching oligosaccharides of certain target glycoproteins, resulting in shorter survival in patients having tumors with low GnT-V expression compared with patients having tumors with high GnT-V expression (Akita 2004; Ishimura et al. 2006; Ito et al. 2001). The importance of this oligosaccharide structure as a precursor to malignancy differs between organs, and the target substrate of GnT-V might differ between oral cancer and other carcinomas. However, from a clinical background, there is not a significant difference with the tumor differentiation with GnT-V expression in OSCC as observed in the other cancer that prognosis was inversely correlated with GnT-V expression. In addition, since expression of GnT-V expression is low in young people, histologic pattern might be different in GnT-V positive and negative cases.

Taken together, immunohistochemistry of OSCC specimens can provide information that could help physicians make appropriate decisions for the treatment of cancer patients. For example, if GnT-V expression is absent, the tumor is more likely to have poor prognosis, and radical treatment in such a case would be a better choice. However, the potential oncogenic role and underlying mechanisms of GnT-V in OSCC have not been investigated. Clearly, further studies are needed to elucidate the mechanisms of GnT-V promoting the development and metastasis of OSCC in detail.

### Table 4 Cox proportional hazards model analysis of prognostic factors in patients

| Characteristics                  | Hazard ratio | 95% CI        | P     |
|----------------------------------|--------------|---------------|-------|
| Age                              | 1.060        | 0.992–1.132   | 0.083 |
| Gender (male/female)             | 0.488        | 0.093–2.565   | 0.397 |
| Alcohol (no alcohol/alcohol drinker) | 1.436        | 0.333–6.199   | 0.627 |
| Smoking (non smoker/smoker)      | 1.814        | 0.444–7.408   | 0.407 |
| Clinical stage (I, II / III, IV) | 2.428        | 0.541–10.896  | 0.247 |
| Differentiation (well/moderate + poor) | 1.016        | 0.286–3.612   | 0.980 |
| GnT-V expression                 | 4.246        | 1.032–17.586  | 0.045 |

Seto et al. SpringerPlus 2013, 2:657
http://www.springerplus.com/content/2/1/657

Received: 28 August 2013 Accepted: 26 November 2013

Published: 6 December 2013

References

Akita H (2004) Molecular biology of lung cancer. Nihon Koyuki Gakkai Zasshi 42(5):378–386

Chen YT, Chong YM, Cheng CW et al (2013) Identification of novel tumor markers for oral squamous cell carcinoma using glycoproteomic analysis. Clin Chim Acta 420:53

Dennis JW, Laferte S, Waghorne C et al (1987) Beta 1–6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 236(4801):582–585

Fernandes B, Sagman U, Auger M et al (1991) Beta 1–6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res 51(2):718–723
Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349(22):2091–2098

Hirai-Fujita Y, Yamamoto-Hino M, Kanie O et al (2008) N-glycosylation of the drosophila neural protein chaoptin is essential for its stability, cell surface transport and adhesive activity. FEBS Lett 582(17):2572–2576

Imamori K, Gu J, Ohira M et al (2006) High expression of N-acetylgalactosaminyltransferase V in favorable neuroblastomas: involvement of its effect on apoptosis. FEBS Lett 580(2):627–632

Ishimura H, Takahashi T, Nakagawa H et al (2008) N-glycosylation of the drosophila neural protein chaoptin is essential for its stability, cell surface transport and adhesive activity. FEBS Lett 582(17):2572–2576

Inamori K, Gu J, Ohira M et al (2006) High expression of N-acetylglucosaminyltransferase V in favorable neuroblastomas: involvement of its effect on apoptosis. FEBS Lett 580(2):627–632

Ito Y, Miyoshi E, Sakon M et al (2001) Elevated expression of UDP-N-acetylgalactosamine: alpha-mannoside beta 1,6 N-acetylgalactosaminyltransferase is an early event in hepatocarcinogenesis. Int J Cancer 91(5):631–637

Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(13):2137–2150

Kishnani V, Bane SM, Kawle PD et al (2005) Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clin Exp Metastasis 22(1):11–24

Lau KS, Dennis JW (2008) N-glycans in cancer progression. Glycobiology 18(10):750–760

Miyoshi E, Terao M, Kamada Y (2012) Physiological roles of N-acetylgalactosaminyltransferase VI (GnT-V) in mice. BMB Rep 45(10):554–559

Murata K, Miyoshi E, Kameyama M et al (2000) Expression of N-acetylgalactosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin Cancer Res 6(5):1772–1777

Nakahara S, Miyoshi E, Noda K et al (2003) Involvement of oligosaccharide changes in alpha5beta1 integrin in a cisplatin-resistant human squamous cell carcinoma cell line. Mol Cancer Ther 2(11):1207–1214

Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108

Rak JW, Basolo F, Elliott JW et al (1991) Cell surface glycosylation changes accompanying immortalization and transformation of normal human mammary epithelial cells. Cancer Lett 57(1):27–36

Saito T, Miyoshi E, Sasaki K et al (2002) A secreted type of beta 1,6-N-acetylgalactosaminyltransferase V (GnT-V) induces tumor angiogenesis without mediation of glycosylation: a novel function of GnT-V distinct from the original glycosyltransferase activity. J Biol Chem 277(19):17002–17008

Saxon E, Bertozzi CR (2001) Chemical and biological strategies for engineering cell surface glycosylation. Annu Rev Cell Dev Biol 17:1–23

Seiwert TY, Cohen EE (2005) State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92(8):1341–1348

Sobin LH, Wittekind C (1997) TNM classification of malignant tumours. Wiley-Liss, Inc., New York

Takahashi N, Yamamoto E, Ino K et al (2009) High expression of N-acetylgalactosaminyltransferase V in mucinous tumors of the ovary. Oncol Rep 22(3):1027–1032

Taniguchi N, Miyoshi E, Ko JH et al (1999) Implication of N-acetylgalactosaminyltransferases III and V in cancer: gene regulation and signaling mechanism. Biochim Biophys Acta 1455(2–3):287–300

Yamamoto E, Ino K, Miyoshi et al (2007) Expression of N-acetylgalactosaminyltransferase V in endometrial cancer correlates with poor prognosis. Br J Cancer 97(11):1538–1544

Zhuo E, He J, Wei T et al (2012) Down-regulation of GnT-V enhances nasopharyngeal carcinoma cell CNE-2 radiosensitivity in vitro and in vivo. Biochem Biophys Res Commun 424(3):554–562

doi:10.1186/2193-1801-2-657
Cite this article as: Seto et al.: Negative expression of N-acetylgalactosaminyltransferase V in oral squamous cell carcinoma correlates with poor prognosis. SpringerPlus 2013 2:657.